Altimmune Consolidated Income vs Operating Expenses Analysis

ALT Stock  USD 8.89  0.24  2.77%   
Trend analysis of Altimmune balance sheet accounts such as Other Current Liab of 17.4 M, Total Current Liabilities of 21.6 M or Total Stockholder Equity of 223.7 M provides information on Altimmune's total assets, liabilities, and equity, which is the actual value of Altimmune to its prevalent stockholders. By breaking down trends over time using Altimmune balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.

About Altimmune Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Altimmune at a specified time, usually calculated after every quarter, six months, or one year. Altimmune Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Altimmune and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Altimmune currently owns. An asset can also be divided into two categories, current and non-current.

Altimmune Balance Sheet Chart

Altimmune Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Altimmune uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Altimmune's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Other Stockholder Equity is likely to gain to about 686.3 M in 2024, whereas Common Stock Total Equity is likely to drop 3,947 in 2024.

Total Assets

Total assets refers to the total amount of Altimmune assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Altimmune books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Altimmune balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Altimmune are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.
Most indicators from Altimmune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Altimmune current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.Tax Provision is likely to gain to 0.00 in 2024, whereas Selling General Administrative is likely to drop slightly above 13.5 M in 2024.
 2021 2022 2023 2024 (projected)
Research Development74.5M70.5M68.1M71.5M
Depreciation And Amortization11.2M2.8M3.3M3.4M

Altimmune fundamental ratios Correlations

0.390.420.86-0.89-0.390.640.930.980.080.810.340.690.440.990.160.68-0.120.02-0.27-0.190.050.210.580.020.84
0.391.0-0.13-0.480.35-0.020.450.440.4-0.11-0.08-0.251.00.420.38-0.11-0.1-0.290.24-0.13-0.22-0.220.93-0.280.33
0.421.0-0.1-0.520.310.020.490.480.41-0.07-0.03-0.211.00.450.4-0.06-0.12-0.310.25-0.15-0.23-0.220.94-0.280.34
0.86-0.13-0.1-0.69-0.60.690.750.81-0.140.930.390.87-0.080.84-0.040.78-0.060.18-0.43-0.120.190.340.110.170.73
-0.89-0.48-0.52-0.690.37-0.46-0.98-0.91-0.25-0.66-0.61-0.55-0.53-0.9-0.3-0.590.250.270.130.30.12-0.07-0.690.03-0.58
-0.390.350.31-0.60.37-0.79-0.44-0.45-0.34-0.76-0.24-0.890.3-0.39-0.44-0.790.490.380.00.470.380.060.150.22-0.31
0.64-0.020.020.69-0.46-0.790.580.650.20.870.020.880.030.630.320.92-0.24-0.12-0.01-0.24-0.150.030.2-0.270.6
0.930.450.490.75-0.98-0.440.580.950.250.740.550.640.50.940.310.69-0.26-0.26-0.15-0.31-0.120.080.67-0.070.64
0.980.440.480.81-0.91-0.450.650.950.220.790.320.70.490.990.30.67-0.26-0.15-0.17-0.31-0.10.10.61-0.070.84
0.080.40.41-0.14-0.25-0.340.20.250.22-0.02-0.010.130.40.140.980.09-0.42-0.650.5-0.36-0.61-0.620.34-0.370.0
0.81-0.11-0.070.93-0.66-0.760.870.740.79-0.020.330.95-0.050.790.10.93-0.2-0.01-0.33-0.250.020.240.17-0.110.68
0.34-0.08-0.030.39-0.61-0.240.020.550.32-0.010.330.28-0.040.33-0.040.35-0.08-0.18-0.14-0.080.050.120.170.19-0.16
0.69-0.25-0.210.87-0.55-0.890.880.640.70.130.950.28-0.190.680.240.91-0.31-0.12-0.23-0.33-0.120.13-0.01-0.10.6
0.441.01.0-0.08-0.530.30.030.50.490.4-0.05-0.04-0.190.470.39-0.05-0.14-0.290.24-0.17-0.24-0.180.94-0.260.36
0.990.420.450.84-0.9-0.390.630.940.990.140.790.330.680.470.210.67-0.09-0.02-0.22-0.160.060.120.6-0.020.84
0.160.380.4-0.04-0.3-0.440.320.310.30.980.1-0.040.240.390.210.21-0.42-0.630.46-0.38-0.6-0.570.35-0.40.09
0.68-0.11-0.060.78-0.59-0.790.920.690.670.090.930.350.91-0.050.670.21-0.16-0.1-0.19-0.19-0.030.140.21-0.240.47
-0.12-0.1-0.12-0.060.250.49-0.24-0.26-0.26-0.42-0.2-0.08-0.31-0.14-0.09-0.42-0.160.7-0.230.980.93-0.08-0.080.07-0.14
0.02-0.29-0.310.180.270.38-0.12-0.26-0.15-0.65-0.01-0.18-0.12-0.29-0.02-0.63-0.10.7-0.370.650.750.52-0.270.490.08
-0.270.240.25-0.430.130.0-0.01-0.15-0.170.5-0.33-0.14-0.230.24-0.220.46-0.19-0.23-0.37-0.05-0.38-0.570.10.04-0.26
-0.19-0.13-0.15-0.120.30.47-0.24-0.31-0.31-0.36-0.25-0.08-0.33-0.17-0.16-0.38-0.190.980.65-0.050.9-0.2-0.130.11-0.21
0.05-0.22-0.230.190.120.38-0.15-0.12-0.1-0.610.020.05-0.12-0.240.06-0.6-0.030.930.75-0.380.90.06-0.150.170.04
0.21-0.22-0.220.34-0.070.060.030.080.1-0.620.240.120.13-0.180.12-0.570.14-0.080.52-0.57-0.20.06-0.090.460.15
0.580.930.940.11-0.690.150.20.670.610.340.170.17-0.010.940.60.350.21-0.08-0.270.1-0.13-0.15-0.09-0.320.38
0.02-0.28-0.280.170.030.22-0.27-0.07-0.07-0.37-0.110.19-0.1-0.26-0.02-0.4-0.240.070.490.040.110.170.46-0.32-0.02
0.840.330.340.73-0.58-0.310.60.640.840.00.68-0.160.60.360.840.090.47-0.140.08-0.26-0.210.040.150.38-0.02
Click cells to compare fundamentals

Altimmune Account Relationship Matchups

Altimmune fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets54.1M245.1M218.9M206.9M238.0M249.9M
Other Current Liab3.6M11.0M6.1M11.8M13.6M17.4M
Total Current Liabilities3.9M12.0M18.3M17.1M19.6M21.6M
Total Stockholder Equity45.5M225.9M199.1M185.3M213.1M223.7M
Net Debt(7.2M)(114.1M)(188.8M)(110.0M)(99.0M)(94.0M)
Retained Earnings(137.4M)(186.4M)(293.2M)(377.9M)(340.1M)(323.1M)
Accounts Payable18.2K612.3K2.0M4.8M5.5M5.8M
Cash9.0M115.9M190.3M111.1M127.8M134.1M
Cash And Short Term Investments37.2M215.9M190.3M184.9M212.6M223.2M
Common Stock Total Equity876.01.5K3.7K4.1K4.7K3.9K
Common Stock Shares Outstanding13.1M25.6M41.3M46.9M54.0M56.7M
Liabilities And Stockholders Equity54.1M245.1M218.9M206.9M238.0M249.9M
Other Current Assets504.4M2.0B13.4B5.4M6.2M5.9M
Other Stockholder Equity187.9M417.3M497.3M568.4M653.7M686.3M
Total Liab8.5M19.2M19.7M21.6M24.9M27.8M
Total Current Assets39.4M230.3M204.1M192.8M221.7M232.8M
Common Stock1.5K3.7K4.1K5K5.8K4.0K
Other Assets128.5K977.2K73.8K19K17.1K16.2K
Non Current Liabilities Total4.6M7.2M1.5M4.6M4.1M4.8M
Short Term Debt259.4K356.7K411.5K452K406.8K386.5K
Short Long Term Debt Total1.7M1.8M1.5M1.1M1.0M961.0K
Property Plant And Equipment Net1.8M2.0M1.4M1.1M972.9K1.5M
Non Current Assets Total14.7M14.9M14.7M14.1M16.2M11.1M
Non Currrent Assets Other128.5K73.4K872.0K615K707.3K486.6K
Net Receivables1.7M12.4M5.8M2.5M2.3M2.2M
Property Plant And Equipment Gross1.8M2.0M1.4M2.6M2.3M1.6M
Accumulated Other Comprehensive Income(5.0M)(5.0M)(5.0M)(5.2M)(4.7M)(4.5M)
Intangible Assets12.7M12.8M12.4M12.4M14.3M11.8M
Net Tangible Assets32.8M213.1M186.7M172.9M198.8M208.7M
Long Term Debt1.9M1.9M1.8M1.5M1.7M1.5M
Retained Earnings Total Equity(116.9M)(137.4M)(186.4M)(293.2M)(337.1M)(354.0M)
Capital Surpluse170.2M187.9M417.3M497.3M571.9M600.5M
Property Plant Equipment1.1M1.1M1.4M1.7M1.9M2.0M
Long Term Debt Total1.9M1.9M1.8M1.5M1.7M2.0M
Non Current Liabilities Other2.8M5.4M1.5M3.9M4.5M4.7M
Other Liab3.1M7.2M330.5K3.9M4.5M3.3M

Altimmune Investors Sentiment

The influence of Altimmune's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Altimmune. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Altimmune's public news can be used to forecast risks associated with an investment in Altimmune. The trend in average sentiment can be used to explain how an investor holding Altimmune can time the market purely based on public headlines and social activities around Altimmune. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Altimmune's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Altimmune's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Altimmune's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Altimmune.

Altimmune Implied Volatility

    
  219.88  
Altimmune's implied volatility exposes the market's sentiment of Altimmune stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Altimmune's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Altimmune stock will not fluctuate a lot when Altimmune's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Altimmune in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Altimmune's short interest history, or implied volatility extrapolated from Altimmune options trading.

Pair Trading with Altimmune

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Altimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Altimmune is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Altimmune Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Altimmune Stock. Highlighted below are key reports to facilitate an investment decision about Altimmune Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for Altimmune Stock analysis

When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Fundamental Analysis
View fundamental data based on most recent published financial statements
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.54)
Revenue Per Share
0.005
Quarterly Revenue Growth
180
Return On Assets
(0.27)
Return On Equity
(0.44)
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.